,

Moderna, Inc. (MRNA) — Fundamental Analysis


  •   4 min reads

Table of content

Moderna is a company in transition — and the numbers make that transition look painful in the rearview mirror but potentially promising in the most recent data. After generating nearly $19 billion in revenue at peak COVID-vaccine demand in 2022, the company has seen revenue collapse sharply as that tailwind faded, and it has been burning cash heavily ever since. For three consecutive fiscal years (2023, 2024, and the full-year 2025 figure), Moderna posted significant operating and net losses. However, the most recent quarterly snapshot — through September 2026 — shows Moderna turning operationally profitable for the first time in years, with positive EBITDA and a double-digit net margin. The balance sheet remains conservative, with minimal debt and a healthy current ratio, suggesting the company has the liquidity runway to execute its pipeline strategy. The big question for investors is whether the Q3 2026 profitability signals a durable recovery or a temporary blip as Moderna works to diversify beyond its COVID franchise.

Snapshot & Big Picture

Moderna built its reputation — and a brief period of extraordinary profitability — on the back of its mRNA COVID-19 vaccine, Spikevax. At the 2021–2022 peak, the company was generating margins that rivaled the best businesses on earth: a net margin above 65% in 2021 and over 43% in 2022 on revenues of roughly $18–19 billion. That era has ended. As COVID vaccination demand normalized globally, revenues fell precipitously: $6.8 billion in 2023, $3.2 billion in 2024, and $1.9 billion in fiscal year 2025 — a staggering contraction. The company has been investing heavily in its next wave of mRNA medicines (respiratory syncytial virus, influenza, personalized cancer vaccines, and more), and those investments are flowing through the income statement as large losses. The key strategic bet is whether that pipeline converts before the cash cushion erodes.

Fiscal Year Revenue EBITDA Operating Margin Net Margin
2016 $108M -$209M -206.4% -199.5%
2017 $206M -$249M -130.9% -124.3%
2018 $135M -$388M -306.0% -284.8%
2019 $60M -$515M -906.8% -853.7%
2020 $803M -$732M -95.0% -93.0%
2021 $18,471M $13,528M +72.0% +66.1%
2022 $19,263M $9,768M +48.9% +43.4%
2023 $6,848M -$3,622M -61.9% -68.8%
2024 $3,236M -$3,760M -121.9% -110.0%
2025 $1,944M -$2,863M -158.1% -145.2%

Latest Quarter Snapshot

The most current data available — Q3 2026, ending September 30, 2026 — is meaningfully more encouraging than the full-year 2025 figures and should be weighted accordingly when assessing Moderna's current trajectory. For the quarter, Moderna reported revenue of $1.313 billion, EBITDA of $191 million, an operating margin of approximately +9.9%, and a net margin of approximately +12.3%. This marks a clear return to profitability at the operating level. The current ratio stands at 3.62, indicating strong short-term liquidity. The debt-to-equity ratio is a modest 0.086, meaning leverage remains very low. Capital expenditures in the quarter were $62 million, or about 4.7% of revenue — a notably lower intensity than recent annual periods, which may reflect the tapering of a major infrastructure buildout cycle. Taken together, Q3 2026 suggests Moderna may be finding its post-COVID equilibrium, though one quarter does not confirm a sustained trend.

Profitability

The multi-year profitability arc is one of the most dramatic in recent biotech history. Moderna spent years pre-2021 as a money-losing clinical-stage company, with operating margins deeply negative due to heavy R&D spending and minimal product revenue. The COVID vaccine transformed that virtually overnight: 2021 and 2022 were years of extraordinary profitability, with EBITDA exceeding $9.7 billion in 2022 alone. The reversal from 2023 onward has been equally dramatic. As vaccine volumes and pricing normalized, revenue fell while operating costs remained elevated — Moderna has explicitly chosen to invest in its pipeline rather than cut aggressively — resulting in widening losses through 2025. The operating margin worsened from -61.9% in 2023 to -158.1% in 2025, reflecting revenue declining faster than expenses. The Q3 2026 return to positive operating margin is a critical inflection point to monitor.

Financial Health & Capital Expenditures

Despite the losses, Moderna's balance sheet has remained resilient. The current ratio has stayed comfortably above 1.0 throughout — ranging from 1.44 in 2020 to 3.89 in recent periods — reflecting the large cash and investment reserves accumulated during the peak vaccine years. Debt has been negligible for most of the company's history; a small debt-to-equity ratio of 0.068 appears in the fiscal 2025 annual data (the metric was not available or not applicable for most prior years), and the Q3 2026 figure of 0.086 confirms leverage remains very modest.

Capital expenditures tell an important story about Moderna's reinvestment cycle. During the pre-commercial years (2016–2019), capex was small in dollar terms but high as a share of revenue simply because revenue was tiny. As the vaccine business scaled in 2021–2022, the company invested significantly in manufacturing infrastructure: capex rose to $284 million in 2021 and $400 million in 2022, though capex-to-revenue ratios were only 1.5% and 2.1% respectively, given the enormous revenue base. As revenue fell post-2022, capex-to-revenue ratios rose sharply — $707 million (10.3% of revenue) in 2023, and a notably elevated $1.051 billion (32.5% of revenue) in 2024, indicating heavy continued infrastructure and pipeline investment even as the top line contracted. By fiscal 2025, capex fell to $192 million (9.9% of revenue), and in Q3 2026 it dropped further to $62 million (4.7% of revenue on a quarterly basis), suggesting capital intensity may finally be normalizing as major buildout phases complete. If this trend holds, it could meaningfully improve free cash flow generation going forward.

Fiscal Year Capital Expenditures CapEx / Revenue
2020 $68M 8.5%
2021 $284M 1.5%
2022 $400M 2.1%
2023 $707M 10.3%
2024 $1,051M 32.5%
2025 $192M 9.9%
Q3 2026 (single quarter) $62M 4.7%

Growth

CAGR Window Start Year End Year Start Revenue End Revenue CAGR
3-Year FY 2022 FY 2025 $19,263M $1,944M -53.4%
5-Year FY 2020 FY 2025 $803M $1,944M +19.3%
10-Year N/A N/A N/A N/A Not available — insufficient filing history extending back 10 fiscal years from 2025

The CAGR figures capture Moderna's whipsaw revenue trajectory in stark terms. The 3-year CAGR of -53.4% (from FY 2022 to FY 2025) reflects the violent post-COVID demand collapse from the company's all-time revenue peak. The 5-year CAGR of +19.3% (from FY 2020 to FY 2025) paints a more balanced picture, anchored to a pre-peak year and showing that net revenue has still grown meaningfully over the broader period. The 10-year window is not available because Moderna's SEC filing history does not extend back a full decade from fiscal year 2025 with sufficient comparable data. Together, these figures underscore that Moderna's near-term growth story is really about stabilization and new product launches rather than extrapolating any historical trend.

Source Filings

Related Posts

↑

The Noise is free. If Phil's commentary made you laugh or think, he accepts tips. No pressure — the sarcasm was complimentary.

Leave a Tip